Invex \u5728\u6210\u5e74 IIH \u60a3\u8005\u4e2d\u8fdb\u884c\u7684 Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u9633\u6027\u6570\u636e\u540e\u5f00\u59cb\u513f\u79d1\u8bd5\u9a8c<\/a>\u3002<\/p>\n\u5efa\u8bae\u8bd5\u7528<\/h2>\n
\u62df\u8bae\u7684\u513f\u79d1\u8bd5\u9a8c\u5c06\u662f\u4e00\u9879\u968f\u673a\u3001\u5b89\u6170\u5242\u5bf9\u7167\u3001\u53cc\u76f2\u3001\u591a\u4e2d\u5fc3\u5f62\u5f0f\uff0c\u62db\u52df\u81f3\u5c11 40 \u540d\u60a3\u6709 IIH \u7684\u9752\u5c11\u5e74\u7537\u6027\u548c\u5973\u6027\uff0c\u4ee5\u53ca\u989d\u5916\u6570\u91cf\u7684\u6210\u5e74\u60a3\u8005\uff0c\u5728 24 \u5468\u5185\u63a5\u53d7 Presendin \u6216\u5b89\u6170\u5242\u6cbb\u7597 \u65f6\u671f\u3002<\/p>\n
\u4e3b\u8981\u7ec8\u70b9\u5c06\u7531\u5728\u8bd5\u9a8c\u8fc7\u7a0b\u4e2d\u901a\u8fc7\u5149\u5b66\u76f8\u5e72\u65ad\u5c42\u626b\u63cf\u8bc4\u4f30\u7684\u4e73\u5934\u6c34\u80bf\uff08\u89c6\u76d8\u80bf\u80c0\uff09\u7684\u53d8\u5316\u6765\u786e\u5b9a\u3002<\/p>\n
\u5173\u952e\u7684\u6b21\u8981\u7ec8\u70b9\u5c06\u5305\u62ec 24 \u5468\u65f6\u7684\u89c6\u91ce\u5e73\u5747\u504f\u5dee\u3001\u5934\u75db\u8bc4\u4f30\u548c\u89c6\u529b\uff0c\u4ee5\u53ca\u6574\u4e2a\u7814\u7a76\u8fc7\u7a0b\u4e2d\u7684\u5b89\u5168\u8bc4\u4f30\u548c\u4f34\u968f\u836f\u7269\u4f7f\u7528\u3002<\/p>\n
\u6700\u7ec8\u8bbe\u8ba1\u5c06\u4ee5 Evolve III \u671f\u8bd5\u9a8c\u7684\u4e34\u5e8a\u7ed3\u679c\u4e3a\u6307\u5bfc\u3002<\/p>\n
\u513f\u79d1\u8bd5\u9a8c\u7684\u79ef\u6781\u7ed3\u679c\u5c06\u4f7f Invex \u5728\u6b27\u6d32\u83b7\u5f97 IIH \u7684\u989d\u5916\u6388\u6743\uff0c\u6269\u5927\u5e02\u573a\u51c6\u5165\uff0c\u4f7f IIH \u53d1\u75c5\u7387\u6301\u7eed\u6500\u5347\u4e14\u76f8\u5173\u533b\u7597\u8d39\u7528\u9ad8\u6602\u7684\u9752\u5c11\u5e74\u4eba\u7fa4\u8fdb\u5165\u5e02\u573a\u3002<\/p>\n
\u9885\u5185\u538b\u5347\u9ad8<\/h2>\n
IIH \u7684\u7279\u70b9\u662f\u9885\u5185\u538b\u4e25\u91cd\u5347\u9ad8\uff0c\u5bfc\u81f4\u6bcf\u5929\u5934\u75db\u5e76\u538b\u8feb\u89c6\u795e\u7ecf\u3002<\/p>\n
\u901a\u5e38\u53d1\u75c5\u5e74\u9f84\u572820\u81f330\u5c81\u4e4b\u95f4\uff0c\u6700\u5e38\u89c1\u4e8e\u80a5\u80d6\u7684\u5973\u6027\u3002<\/p>\n
IIH \u662f\u4e00\u79cd\u5feb\u901f\u589e\u957f\u7684\u5b64\u513f\u9002\u5e94\u75c7\uff0c\u5176\u53d1\u75c5\u7387\u5728\u8fc7\u53bb 10 \u5e74\u4e2d\u589e\u52a0\u4e86 350% \u4ee5\u4e0a\u3002<\/p>\n
\u5728\u82f1\u56fd\uff0cIIH \u7684\u513f\u79d1\u603b\u53d1\u75c5\u7387\u7ea6\u4e3a\u6bcf 100,000 \u4eba 0.7 \u4f8b\u3002<\/p>\n","protected":false},"excerpt":{"rendered":"
Invex Therapeutics (ASX: IXC) \u63d0\u4ea4\u7684\u513f\u79d1\u8c03\u67e5\u8ba1\u5212 (PIP) \u7528\u4e8e\u5f00\u53d1\u6cbb\u7597\u9752\u5c11\u5e74\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5148\u5bfc\u836f\u7269 Presendin\uff0c\u5df2\u88ab\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08European Medicines Agency\uff09\u63a5\u53d7\u3002 \u8be5\u6279\u51c6\u5c06\u5141\u8bb8 Invex \u4e3a 18 \u5c81\u4ee5\u4e0b\u4e14\u5df2\u8fdb\u5165\u9752\u6625\u671f\u7684 IIH \u60a3\u8005\u5f00\u53d1 Presendin\u3002 PIP \u5305\u62ec\u4e00\u9879\u51b3\u5b9a\uff0c\u5373\u8c41\u514d Invex \u5728 12 \u5c81\u4ee5\u4e0b\u7684\u9752\u6625\u671f\u524d\u7537\u6027\u548c\u5973\u6027\u4e2d\u8fdb\u884c\u8bd5\u9a8c\u3002 \u5b83\u8fd8\u5305\u62ec\u5ef6\u671f\uff0c\u5141\u8bb8\u5728\u6536\u5230 Invex \u5728\u6210\u5e74 IIH \u60a3\u8005\u4e2d\u8fdb\u884c\u7684 Evolve III \u671f\u4e34\u5e8a\u8bd5\u9a8c\u7684\u9633\u6027\u6570\u636e\u540e\u5f00\u59cb\u513f\u79d1\u8bd5\u9a8c\u3002 \u5efa\u8bae\u8bd5\u7528 \u62df\u8bae\u7684\u513f\u79d1\u8bd5\u9a8c\u5c06\u662f\u4e00\u9879\u968f\u673a\u3001\u5b89\u6170\u5242\u5bf9\u7167\u3001\u53cc\u76f2\u3001\u591a\u4e2d\u5fc3\u5f62\u5f0f\uff0c\u62db\u52df\u81f3\u5c11 40 \u540d\u60a3\u6709 IIH \u7684\u9752\u5c11\u5e74\u7537\u6027\u548c\u5973\u6027\uff0c\u4ee5\u53ca\u989d\u5916\u6570\u91cf\u7684\u6210\u5e74\u60a3\u8005\uff0c\u5728 24 \u5468\u5185\u63a5\u53d7 Presendin \u6216\u5b89\u6170\u5242\u6cbb\u7597 \u65f6\u671f\u3002 \u4e3b\u8981\u7ec8\u70b9\u5c06\u7531\u5728\u8bd5\u9a8c\u8fc7\u7a0b\u4e2d\u901a\u8fc7\u5149\u5b66\u76f8\u5e72\u65ad\u5c42\u626b\u63cf\u8bc4\u4f30\u7684\u4e73\u5934\u6c34\u80bf\uff08\u89c6\u76d8\u80bf\u80c0\uff09\u7684\u53d8\u5316\u6765\u786e\u5b9a\u3002 \u5173\u952e\u7684\u6b21\u8981\u7ec8\u70b9\u5c06\u5305\u62ec 24 \u5468\u65f6\u7684\u89c6\u91ce\u5e73\u5747\u504f\u5dee\u3001\u5934\u75db\u8bc4\u4f30\u548c\u89c6\u529b\uff0c\u4ee5\u53ca\u6574\u4e2a\u7814\u7a76\u8fc7\u7a0b\u4e2d\u7684\u5b89\u5168\u8bc4\u4f30\u548c\u4f34\u968f\u836f\u7269\u4f7f\u7528\u3002 \u6700\u7ec8\u8bbe\u8ba1\u5c06\u4ee5 Evolve III \u671f\u8bd5\u9a8c\u7684\u4e34\u5e8a\u7ed3\u679c\u4e3a\u6307\u5bfc\u3002 \u513f\u79d1\u8bd5\u9a8c\u7684\u79ef\u6781\u7ed3\u679c\u5c06\u4f7f Invex… Continue reading Invex Therapeutics \u83b7\u5f97\u6b27\u76df\u6279\u51c6\u4e3a\u60a3\u6709\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u75c7\u7684\u9752\u5c11\u5e74\u5f00\u53d1 Presendin<\/span><\/a><\/p>\n","protected":false},"author":4,"featured_media":18384,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[3],"tags":[273],"yoast_head":"\nInvex Therapeutics \u83b7\u5f97\u6b27\u76df\u6279\u51c6\u4e3a\u60a3\u6709\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u75c7\u7684\u9752\u5c11\u5e74\u5f00\u53d1 Presendin<\/title>\n<meta name=\"description\" content=\"Invex Therapeutics (ASX: IXC) \u63d0\u4ea4\u7684\u513f\u79d1\u8c03\u67e5\u8ba1\u5212 (PIP) \u7528\u4e8e\u5f00\u53d1\u6cbb\u7597\u9752\u5c11\u5e74\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5148\u5bfc\u836f\u7269 Presendin\uff0c\u5df2\u88ab\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08European Medicines Agency\uff09\u63a5\u53d7\u3002\" \/>\n<meta name=\"robots\" content=\"noindex, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invex Therapeutics \u83b7\u5f97\u6b27\u76df\u6279\u51c6\u4e3a\u60a3\u6709\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u75c7\u7684\u9752\u5c11\u5e74\u5f00\u53d1 Presendin\" \/>\n<meta property=\"og:description\" content=\"Invex Therapeutics (ASX: IXC) \u63d0\u4ea4\u7684\u513f\u79d1\u8c03\u67e5\u8ba1\u5212 (PIP) \u7528\u4e8e\u5f00\u53d1\u6cbb\u7597\u9752\u5c11\u5e74\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5148\u5bfc\u836f\u7269 Presendin\uff0c\u5df2\u88ab\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08European Medicines Agency\uff09\u63a5\u53d7\u3002\" \/>\n<meta property=\"og:url\" content=\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-eu-approval-presendin-adolescents-idiopathic-intracranial-hypertension\/\" \/>\n<meta property=\"og:site_name\" content=\"smallcapsCN\" \/>\n<meta property=\"article:published_time\" content=\"2022-12-13T23:51:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-08-29T17:56:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-EU-approval-Presendin-adolescents-idiopathic-intracranial-hypertension-IIH-European-Medicines-Agency-EMA-Paediatric-Committee-PDCO.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"640\" \/>\n\t<meta property=\"og:image:height\" content=\"400\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Imelda Cotton\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Imelda Cotton\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-eu-approval-presendin-adolescents-idiopathic-intracranial-hypertension\/\",\"url\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-eu-approval-presendin-adolescents-idiopathic-intracranial-hypertension\/\",\"name\":\"Invex Therapeutics \u83b7\u5f97\u6b27\u76df\u6279\u51c6\u4e3a\u60a3\u6709\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u75c7\u7684\u9752\u5c11\u5e74\u5f00\u53d1 Presendin\",\"isPartOf\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\"},\"datePublished\":\"2022-12-13T23:51:11+00:00\",\"dateModified\":\"2023-08-29T17:56:30+00:00\",\"author\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\"},\"description\":\"Invex Therapeutics (ASX: IXC) \u63d0\u4ea4\u7684\u513f\u79d1\u8c03\u67e5\u8ba1\u5212 (PIP) \u7528\u4e8e\u5f00\u53d1\u6cbb\u7597\u9752\u5c11\u5e74\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5148\u5bfc\u836f\u7269 Presendin\uff0c\u5df2\u88ab\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08European Medicines Agency\uff09\u63a5\u53d7\u3002\",\"breadcrumb\":{\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-eu-approval-presendin-adolescents-idiopathic-intracranial-hypertension\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-eu-approval-presendin-adolescents-idiopathic-intracranial-hypertension\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-eu-approval-presendin-adolescents-idiopathic-intracranial-hypertension\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/smallcapscn.x5view.co\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invex Therapeutics \u83b7\u5f97\u6b27\u76df\u6279\u51c6\u4e3a\u60a3\u6709\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u75c7\u7684\u9752\u5c11\u5e74\u5f00\u53d1 Presendin\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#website\",\"url\":\"https:\/\/smallcapscn.x5view.co\/\",\"name\":\"smallcapsCN\",\"description\":\"Just another WordPress site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e\",\"name\":\"Imelda Cotton\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g\",\"caption\":\"Imelda Cotton\"},\"description\":\"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.\",\"url\":\"https:\/\/smallcapscn.x5view.co\/?author=4\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Invex Therapeutics \u83b7\u5f97\u6b27\u76df\u6279\u51c6\u4e3a\u60a3\u6709\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u75c7\u7684\u9752\u5c11\u5e74\u5f00\u53d1 Presendin","description":"Invex Therapeutics (ASX: IXC) \u63d0\u4ea4\u7684\u513f\u79d1\u8c03\u67e5\u8ba1\u5212 (PIP) \u7528\u4e8e\u5f00\u53d1\u6cbb\u7597\u9752\u5c11\u5e74\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5148\u5bfc\u836f\u7269 Presendin\uff0c\u5df2\u88ab\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08European Medicines Agency\uff09\u63a5\u53d7\u3002","robots":{"index":"noindex","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"og_locale":"en_US","og_type":"article","og_title":"Invex Therapeutics \u83b7\u5f97\u6b27\u76df\u6279\u51c6\u4e3a\u60a3\u6709\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u75c7\u7684\u9752\u5c11\u5e74\u5f00\u53d1 Presendin","og_description":"Invex Therapeutics (ASX: IXC) \u63d0\u4ea4\u7684\u513f\u79d1\u8c03\u67e5\u8ba1\u5212 (PIP) \u7528\u4e8e\u5f00\u53d1\u6cbb\u7597\u9752\u5c11\u5e74\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5148\u5bfc\u836f\u7269 Presendin\uff0c\u5df2\u88ab\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08European Medicines Agency\uff09\u63a5\u53d7\u3002","og_url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-eu-approval-presendin-adolescents-idiopathic-intracranial-hypertension\/","og_site_name":"smallcapsCN","article_published_time":"2022-12-13T23:51:11+00:00","article_modified_time":"2023-08-29T17:56:30+00:00","og_image":[{"width":640,"height":400,"url":"https:\/\/smallcapscn.x5view.co\/wp-content\/uploads\/2023\/08\/Invex-Therapeutics-ASX-IXC-EU-approval-Presendin-adolescents-idiopathic-intracranial-hypertension-IIH-European-Medicines-Agency-EMA-Paediatric-Committee-PDCO.jpg","type":"image\/jpeg"}],"author":"Imelda Cotton","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Imelda Cotton"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-eu-approval-presendin-adolescents-idiopathic-intracranial-hypertension\/","url":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-eu-approval-presendin-adolescents-idiopathic-intracranial-hypertension\/","name":"Invex Therapeutics \u83b7\u5f97\u6b27\u76df\u6279\u51c6\u4e3a\u60a3\u6709\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u75c7\u7684\u9752\u5c11\u5e74\u5f00\u53d1 Presendin","isPartOf":{"@id":"https:\/\/smallcapscn.x5view.co\/#website"},"datePublished":"2022-12-13T23:51:11+00:00","dateModified":"2023-08-29T17:56:30+00:00","author":{"@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e"},"description":"Invex Therapeutics (ASX: IXC) \u63d0\u4ea4\u7684\u513f\u79d1\u8c03\u67e5\u8ba1\u5212 (PIP) \u7528\u4e8e\u5f00\u53d1\u6cbb\u7597\u9752\u5c11\u5e74\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b (IIH) \u7684\u5148\u5bfc\u836f\u7269 Presendin\uff0c\u5df2\u88ab\u6b27\u6d32\u836f\u54c1\u7ba1\u7406\u5c40\uff08European Medicines Agency\uff09\u63a5\u53d7\u3002","breadcrumb":{"@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-eu-approval-presendin-adolescents-idiopathic-intracranial-hypertension\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/smallcapscn.x5view.co\/invex-therapeutics-eu-approval-presendin-adolescents-idiopathic-intracranial-hypertension\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/smallcapscn.x5view.co\/invex-therapeutics-eu-approval-presendin-adolescents-idiopathic-intracranial-hypertension\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/smallcapscn.x5view.co\/"},{"@type":"ListItem","position":2,"name":"Invex Therapeutics \u83b7\u5f97\u6b27\u76df\u6279\u51c6\u4e3a\u60a3\u6709\u7279\u53d1\u6027\u9885\u5185\u9ad8\u538b\u75c7\u7684\u9752\u5c11\u5e74\u5f00\u53d1 Presendin"}]},{"@type":"WebSite","@id":"https:\/\/smallcapscn.x5view.co\/#website","url":"https:\/\/smallcapscn.x5view.co\/","name":"smallcapsCN","description":"Just another WordPress site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/smallcapscn.x5view.co\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/cb7c1f9e2fb318e8ea5882e380e0d90e","name":"Imelda Cotton","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/smallcapscn.x5view.co\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/171e68cb4a3261dde883daa03441bfa3?s=96&d=mm&r=g","caption":"Imelda Cotton"},"description":"Imelda Cotton has over 20 years experience as a journalist and communications professional. She has spent the bulk of her career in the resources sector, having also worked directly with oil and gas majors and as a journalist covering a vast array of ASX listed companies within the resources, energy, science and health sectors.","url":"https:\/\/smallcapscn.x5view.co\/?author=4"}]}},"_links":{"self":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6212"}],"collection":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=6212"}],"version-history":[{"count":1,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6212\/revisions"}],"predecessor-version":[{"id":16091,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/posts\/6212\/revisions\/16091"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=\/wp\/v2\/media\/18384"}],"wp:attachment":[{"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=6212"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=6212"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/smallcapscn.x5view.co\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=6212"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}